Equities analysts forecast that Urogen Pharma Ltd (NASDAQ:URGN) will post earnings of ($1.20) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Urogen Pharma’s earnings. The highest EPS estimate is ($1.11) and the lowest is ($1.33). Urogen Pharma reported earnings per share of ($1.14) during the same quarter last year, which would suggest a negative year-over-year growth rate of 5.3%. The business is scheduled to announce its next earnings report on Tuesday, August 13th.
On average, analysts expect that Urogen Pharma will report full-year earnings of ($5.37) per share for the current year, with EPS estimates ranging from ($5.83) to ($4.82). For the next year, analysts expect that the company will report earnings of ($4.23) per share, with EPS estimates ranging from ($6.33) to ($1.66). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Urogen Pharma.
Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.12) by $0.01. Urogen Pharma had a negative return on equity of 61.24% and a negative net margin of 4,296.08%.
NASDAQ URGN traded up $0.15 on Monday, hitting $35.40. 8,395 shares of the stock traded hands, compared to its average volume of 136,165. The company has a 50-day moving average price of $36.89. Urogen Pharma has a twelve month low of $33.37 and a twelve month high of $56.91. The stock has a market capitalization of $484.69 million, a P/E ratio of -7.33 and a beta of 1.31.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado bought a new stake in Urogen Pharma during the 1st quarter worth about $41,000. Parallel Advisors LLC boosted its holdings in Urogen Pharma by 100.0% in the 4th quarter. Parallel Advisors LLC now owns 1,000 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Urogen Pharma by 100.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock valued at $74,000 after purchasing an additional 1,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Urogen Pharma by 112.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after purchasing an additional 1,282 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in Urogen Pharma by 27.6% in the 4th quarter. Van ECK Associates Corp now owns 4,364 shares of the company’s stock valued at $188,000 after purchasing an additional 944 shares during the period. 97.86% of the stock is currently owned by institutional investors and hedge funds.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.